Gilead Sciences Aktie News

Investors love growth stocks that also pay big and reliable dividends because they provide dependable passive income streams and an excellent opportunity for solid total return.

The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.

LOS ANGELES--(BUSINESS WIRE)--AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention.

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS)'s twice-yearly injectable HIV prevention drug lenacapavir is on track for a solid launch after being officially approved by the US Food and Drug Administration (FDA) on Wednesday, analysts at Jefferies believe. Lenacapavir, marketed as Yeztugo, is the first pre-exposure prophylaxis (PrEP) drug requiring only two treatments per year, offering a signific...

Gilead Sciences won Food and Drug Administration approval Wednesday for a highly effective drug to prevent HIV infection.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company's injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly op...

The Food and Drug Administration approved Gilead's twice-yearly antiviral drug for preventing HIV. The company and some experts say it is a milestone that could help bring the world closer to ending the decades-long epidemic caused by the virus.

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.